114,968 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Bought by Royce & Associates LP

Royce & Associates LP bought a new stake in Astrana Health, Inc. (NASDAQ:ASTH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 114,968 shares of the company’s stock, valued at approximately $6,661,000. Royce & Associates LP owned about 0.23% of Astrana Health as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC purchased a new stake in shares of Astrana Health in the 3rd quarter worth about $34,000. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health in the third quarter valued at about $35,000. KBC Group NV acquired a new stake in shares of Astrana Health in the third quarter valued at approximately $70,000. Central Pacific Bank Trust Division purchased a new position in shares of Astrana Health during the 3rd quarter worth approximately $160,000. Finally, Everence Capital Management Inc. acquired a new position in shares of Astrana Health during the 3rd quarter worth approximately $272,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ASTH shares. KeyCorp started coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Stifel Nicolaus boosted their target price on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Truist Financial upped their target price on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th. BTIG Research lifted their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. Finally, TD Cowen initiated coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $65.17.

Astrana Health Price Performance

ASTH opened at $40.81 on Monday. Astrana Health, Inc. has a 1 year low of $32.04 and a 1 year high of $63.20. The company’s 50 day simple moving average is $55.04 and its 200 day simple moving average is $47.81. The stock has a market capitalization of $2.30 billion, a PE ratio of 31.39, a P/E/G ratio of 1.89 and a beta of 1.24. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.84 and a current ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same quarter last year, the business earned $0.47 EPS. As a group, sell-side analysts expect that Astrana Health, Inc. will post 1.17 EPS for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.